What Happened?
Shares of oncology (cancer) diagnostics company NeoGenomics (NASDAQ: NEO) jumped 15.8% in the afternoon session after the company reported second-quarter 2026 earnings that surpassed Wall Street expectations and raised its full-year financial guidance.
The cancer-diagnostics company posted adjusted earnings of $0.05 per share on revenue of $201.7 million, beating analyst forecasts of $0.03 per share and $197.3 million in revenue. The top-line result represented an 11.2% increase compared to the same period in the previous year.
Following the strong performance, NeoGenomics lifted its full-year outlook, now expecting revenue of around $804 million. Furthermore, its adjusted earnings per share guidance for the full year of $0.19 also came in ahead of analyst estimates.
Is now the time to buy NeoGenomics? Access our full analysis report here, it’s free.
What Is The Market Telling Us
NeoGenomics’s shares are very volatile and have had 28 moves greater than 5% over the last year. But moves this big are rare even for NeoGenomics and indicate this news significantly impacted the market’s perception of the business.
The previous big move we wrote about was 20 days ago when the stock gained 3.4% on the news that the company announced the launch of the first FDA-approved immunohistochemistry (IHC) companion diagnostic test for patients with prostate cancer. The test, called PTEN IHC CDx, is designed to identify PTEN protein loss in patients with prostate adenocarcinoma. This detection is crucial as it helps determine which patients may be eligible for AstraZeneca's recently approved targeted therapy, TRUQAP. By providing a necessary diagnostic tool for a specific, modern treatment, NeoGenomics has established a clear commercial application for its product, linking it directly to patient care decisions and a major pharmaceutical therapy.
NeoGenomics is up 32.9% since the beginning of the year, and at $15.63 per share, it has set a new 52-week high. Despite the year-to-date gain, investors who bought $1,000 worth of NeoGenomics’s shares 5 years ago would now be looking at only $342.08.
ONE MORE THING: 3 Hidden Platforms Growing 3X Faster than Amazon, Google, and PayPal. Amazon, Google, and Meta all followed the same playbook: Dominate an ignored market. Build an unbeatable moat. Scale until you’re unstoppable.
These three platforms are running that exact playbook right now. The early investors in Amazon made fortunes. The early investors in these could do the same. Get All 3 Stocks Here for FREE.
